Novo Nordisk, the pharma company behind Wegovy, faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
